Dinac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dinac

Dinac Quick Facts

Property Description
Active ingredient Diclofenac (e.g., Diclofenac Sodium)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic (chemically manufactured)
Single/Combination Single-ingredient product

What Type of Medicine is Dinac and What is its Composition?

Dinac is a pharmaceutical preparation whose active substance is Diclofenac, classifying it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This compound is a member of the Phenylacetic Acid derivative class and is entirely synthetic in origin, meaning it is chemically manufactured. The core efficacy of the drug is derived from Diclofenac's function as a cyclooxygenase (COX) inhibitor. The drug's mechanism provides a dual action, offering potent relief from physical discomfort while simultaneously reducing swelling.

Available Forms and Therapeutic Purpose

The general therapeutic purpose of this single-ingredient product is to act as a potent systemic and localized analgesic and anti-inflammatory agent. The consistent action of Diclofenac is clinically recognized for its efficacy in managing acute inflammatory conditions, such as providing short-term relief for sprains. Dinac is produced in various dosage forms, including oral tablets, topical gels, and injectable solutions, allowing flexibility in treatment delivery.

Diclofenac is categorized as an essential medicine required for a basic healthcare system. Consequently, the availability of diverse forms ensures that the medication can be administered via oral, topical, or parenteral routes, optimizing its application depending on the therapeutic need, for example, utilizing a topical gel for muscle strain versus an oral tablet for generalized fever and pain.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Dinac?

Possible Side Effects and Safety Information

The official safety profile for Dinac (Diclofenac) outlines potential risks across several body systems, with adverse reactions formally classified by their frequency according to regulatory standards (e.g., EMA/FDA).


Key Regulatory Safety Classifications

Classification Examples of Officially Documented Adverse Reactions
Common Gastrointestinal disturbances (e.g., abdominal pain, nausea), headache, dizziness, increased liver enzymes.
Rare/Very Rare Hypersensitivity, severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), agranulocytosis, acute renal failure, hepatitis, and jaundice.

Serious Adverse Reactions and Systemic Risks

Regulatory documents highlight the potential for Serious Cardiovascular Thrombotic Events, including Myocardial Infarction and Stroke, which may occur early in treatment and whose risk may increase with higher doses and prolonged use. Serious Gastrointestinal Adverse Events—such as bleeding, ulceration, and perforation—are also a focus, capable of occurring without warning symptoms.

Adverse effects are grouped by System-Organ Classes, primarily involving the Gastrointestinal, Cardiovascular, Renal/Urinary, and Hepatobiliary systems.

Population and Duration-Related Safety

Official labeling defines specific constraints: the medication is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with known aspirin-sensitive asthma. Furthermore, use is generally avoided in older adults due to increased gastrointestinal risk, and in late-stage pregnancy (at or after 30 weeks gestation) due to risks to the fetus.

Overdose and Emergency Response

Overdose: When to Seek Urgent Medical Help

Dinac is a type of Non-Steroidal Anti-Inflammatory Drug (NSAID). While most instances of accidental or minor overdose remain asymptomatic or result in minor, self-limiting discomfort, a significant overdose can lead to severe toxicity. It is essential to recognize the signs of poisoning and understand the necessary emergency steps.

Documented Overdose Symptoms

The primary symptoms observed after an acute overdose typically involve the central nervous system (CNS) and the gastrointestinal (GI) tract. These can include:

  • Gastrointestinal: Nausea, vomiting, epigastric (upper stomach) pain, diarrhea, and potentially gastrointestinal bleeding.
  • Central Nervous System (CNS): Drowsiness, disorientation, excitation, tinnitus (ringing in the ears), and, in more severe cases, convulsions or coma.

Serious Complications

Significant poisoning poses a risk for critical physiological damage, specifically acute renal failure (sudden kidney damage) and liver damage.

Emergency Response and Medical Care

Seek medical attention immediately following any suspected overdose or ingestion of excessive amounts. Contacting a poison control center or emergency services is the first essential step. The general medical management for Dinac overdose is symptomatic and supportive treatment to maintain vital functions and address specific symptoms as they arise.

Treatment may involve measures to reduce the absorption of the drug from the GI tract, such as administering activated charcoal. In severe cases, especially those with evidence of severe organ damage (e.g., acute renal failure), specialized medical procedures may be required to support the affected systems.

Therapeutic Uses of Dinac

The medication is commonly used across therapeutic domains where additional symptomatic support is needed to help ease symptoms related to inflammatory or irritative states. Dinac is considered relevant in conditions where symptoms create noticeable physiological strain and may interfere with functional stability. This medication is recognized for its broad application within these therapeutic contexts.

Therapeutic Uses and Symptom Support

Dinac plays a role in managing symptom clusters that may become intense or disruptive over time in long-term joint diseases, specifically osteoarthritis and rheumatoid arthritis. It is also applied in acute symptomatic episodes, including migraine attacks, symptoms related to temporary discomfort after procedures, and the challenging discomfort of menstrual cramps (dysmenorrhea). The medication helps to manage symptoms that interfere with daily comfort, which may assist with maintaining functional stability.


Quick Fact: Support for Joint Pain and Stiffness Dinac is commonly used to help ease the symptoms of joint pain, stiffness, and associated swelling related to long-term inflammatory conditions, contributing to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for Dinac (Diclofenac) is strictly defined by regulatory bodies based on a patient's medical history, age, and existing health conditions. Use is generally established for adults but becomes restricted or prohibited in specific populations.

Who Must Not Use Dinac (Contraindications)

Dinac is contraindicated (must not be used) in patients with the following conditions, as stated in the official labels:

  • Known Hypersensitivity to Diclofenac or any other Nonsteroidal Anti-inflammatory Drug (NSAID), including those who have a history of asthma, hives, or allergic-type reactions after taking aspirin.
  • Established Cardiovascular Disease (systemic forms) such as congestive heart failure (NYHA Class II-IV), ischaemic heart disease, or cerebrovascular disease (European guidance).
  • Peri-operative Pain in the setting of coronary artery bypass graft (CABG) surgery.
  • Late-Stage Pregnancy starting at 30 weeks gestation (third trimester) due to documented fetal risk.

Conditional Use and Restrictions

Population Regulatory Status
Pediatric Patients Safety and effectiveness are not established for many formulations in children under 12 years of age.
Older Adults At greater risk for serious gastrointestinal and cardiovascular events; use requires careful consideration.
Renal/Hepatic Impairment Avoid use in advanced renal disease; use with caution in hepatic impairment due to metabolism concerns.
Breastfeeding Use is not recommended due to the drug's excretion into breast milk.

These constraints establish the boundaries for legal and safe patient eligibility.

What should I know about interactions with other medicines?

Dinac Interactions with other medicines and products

Dinac (Diclofenac) has officially documented interaction patterns that regulate its co-administration with other medicinal products and certain medical conditions. All interaction statements are derived from authoritative government regulatory sources.

Contraindicated and High-Risk Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin, is not generally recommended due to an officially documented risk of additive gastrointestinal (GI) adverse effects. Dinac is contraindicated for the treatment of perioperative pain related to Coronary Artery Bypass Graft (CABG) surgery and in patients with established cardiovascular conditions, including congestive heart failure (NYHA II–IV), ischemic heart disease, and cerebrovascular disease.

Exposure and Pharmacodynamic Effects

Co-administration with the strong enzyme inhibitor Voriconazole is officially documented to cause a significant increase in Dinac's plasma exposure (AUC/Cmax). Conversely, Dinac can raise the plasma concentrations of substances like Lithium, Digoxin, and Phenytoin due to reduced renal clearance.

Pharmacodynamically, Dinac has a synergistic effect on bleeding risk when combined with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, or Systemic Corticosteroids. Dinac also officially diminishes the effectiveness of ACE Inhibitors, Angiotensin II Antagonists, and Diuretics by reducing their antihypertensive and natriuretic effects. Use with Cyclosporine may also lead to increased nephrotoxicity.

Administration Restrictions

Official regulatory documents specify that Dinac (NSAID) dosing must be interrupted for a period of time both before and after the administration of Pemetrexed to manage toxicity risk. Consumption of alcohol is also documented to increase the risk of serious GI bleeding when combined with Dinac.

Mechanism of Action

Dinac (Diclofenac) exerts its functional consequences through specific molecular interactions that modulate key physiological pathways associated with inflammatory responses. Its mechanism is rooted in chemical interference with signal-generating enzymes, not receptor agonism or direct neural blockade.

Suppression of Prostaglandin Synthesis via COX Inhibition

The core mechanism involves the competitive inhibition of Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and the inducible COX-2 enzyme. This molecular action directly prevents the conversion of arachidonic acid into prostanoids, such as Prostaglandin E2 (PGE2), which are crucial chemical mediators. The suppression of PGE2 production structurally limits the downstream effects, including vascular responses and nerve sensitization, which are critical steps in the overall physiological reaction.

Desensitization of Peripheral Pain Signaling

The overall mechanism leads to the desensitization of peripheral nociceptors (pain-sensing nerve endings) in affected tissues. This is primarily achieved by removing the PGE2 that normally sensitizes these nerves, effectively reducing their excitability. The consequence is a substantial limitation in the generation and transmission of pain signals back toward the central nervous system, establishing the drug's anti-nociceptive physiological consequence.

Central Thermoregulatory Adjustment

In addition to peripheral effects, the drug acts centrally to affect the hypothalamus, the brain region responsible for controlling core body temperature. By inhibiting COX activity within the CNS, it suppresses the PGE2 signals that elevate the thermoregulatory set-point, which results in the adjustment of the elevated thermoregulatory set-point.

Dosage and Administration Information

The use of Dinac (Diclofenac) is guided by established clinical parameters that define its delivery, dosage limits, and duration of administration. The medication is approved for administration via multiple routes, including oral (tablets, capsules, and solution packets), topical (gels and solutions), rectal (suppositories), and parenteral (intramuscular and intravenous infusion).

The overarching principle for administration is to employ the lowest effective dosage for the shortest duration necessary to meet individual treatment objectives. Standard adult oral regimens vary, with total daily doses typically ranging between 100 mg and 200 mg in divided amounts, depending on the specific formulation. Maximum daily doses are strictly established and must not be exceeded.

In terms of intake conditions, Immediate-Release oral forms are often recommended to be taken before meals for optimal absorption, while Delayed-Release tablets may be taken with food. A crucial procedural rule is that all tablets must be swallowed whole and are not to be crushed, split, or chewed to maintain their designed release profile. Parenteral administration, such as by injection or infusion, is constrained and intended for short-term use only, with initial courses typically limited to no more than two days.

For specific populations, clinical guidance indicates that older adults should be given the lowest effective dosage. No routine adjustment to the oral dosage is generally required for patients with mild to moderate renal dysfunction. Topical applications must be applied to clean, intact skin, and standard clinical guidance restricts the use of airtight occlusive dressings over the treated area.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dinac


Evidence for Chronic Inflammatory Joint Conditions

Dinac was evaluated in research exploring conditions characterized by functional limitations and outcomes related to physical discomfort, specifically in the long-term study of osteoarthritis (OA) and rheumatoid arthritis (RA). Researchers utilized numerous short- to intermediate-term Randomized Controlled Trials (RCTs) and longer-term observational studies in studies examining patient-reported experiences. The studies primarily examined outcomes related to pain intensity, changes in daily functioning or activity level, and stiffness reported by adults and older adults with these conditions. Findings help contextualize how patients reported their experience, particularly concerning pain and movement associated with OA and RA.

Evidence for Acute Localized Musculoskeletal Pain

Research examined Dinac’s topical formulations (such as gels or patches) in studies focusing on conditions associated with acute or disruptive episodes, including localized injuries like sprains, strains, and tendinitis. Studies conducted during periods of increased symptom activity primarily used short-term RCTs that focused on outcomes describing episodic or acute changes. The main outcomes research examined were patient-reported outcomes describing perceived discomfort and the need for rescue medication over defined time intervals. Follow-up durations were limited, as the vast majority of this research exploring short-term symptom changes only tracked patients for periods up to 14 days.

Evidence for Systemic Acute Pain Syndromes

Dinac was evaluated in research contexts involving fluctuating or unstable symptoms, such as migraine attacks and primary dysmenorrhea (menstrual cramps). These placebo-controlled RCTs research examined outcomes capturing phases of heightened symptom activity. Trials reported patterns related to the proportion of individuals who reported changes in outcomes linked to physical discomfort, such as becoming pain-free or reaching a defined symptom relief endpoint at specific, short time intervals. The studies provide limited information for long-term outcomes or continuous usage patterns.

What is Still Uncertain About Dinac Research

The evidence highlights what is known—and what is still uncertain; research does not determine whether an individual will respond similarly. A key limitation is that follow-up durations were limited in many controlled trials, particularly for evaluating sustained outcomes over multiple years. Data are still emerging for some newer formulations and specific subgroups. The evidence quality varies across studies, and comparative evidence against the full scope of therapeutic alternatives is still emerging.

Key Studies & References

  1. Diclofenac for acute postoperative pain in children (Cochrane Review) (Used for Special Populations evidence gap)

Frequently Asked Questions (FAQ)

Common questions about Dinac (FAQ)


Q: How quickly should I expect Dinac to start working?

A: Studies on the drug's properties indicate that the active substance can reach its highest concentration in the bloodstream approximately three hours after taking a typical oral dose. The speed at which it begins to be absorbed can depend on the specific formulation and whether it is consumed with food. Regulatory pharmacokinetic data describes the rate of absorption, but how an individual experiences the start of the therapeutic action can vary.

Q: How long does Dinac stay in your system after stopping treatment?

A: The active substance in Dinac has a relatively short elimination half-life, which is the measure of time required for half the drug to leave the body. The rapid elimination half-life suggests the substance is generally cleared from the bloodstream within a short timeframe after the last dose. Final elimination time can vary based on individual metabolism.

Q: Can Dinac affect sleep patterns?

A: Official safety documents describe certain central nervous system effects reported by some users, which can include dizziness and headache. Less commonly, some regulatory reports have noted insomnia (difficulty sleeping) and nightmares as potential adverse reactions. Patients who report sleep changes should communicate these observations to their healthcare provider.

Q: Does taking Dinac make you tired or drowsy?

A: The official safety profile documents drowsiness (somnolence) as a reported adverse reaction for Dinac. Due to this potential effect, regulatory warnings advise caution when performing activities that require alertness, such as driving or operating machinery.

Q: Can Dinac cause changes in mood or anxiety?

A: The official safety profile includes psychiatric adverse reactions documented in rare instances. These documented effects can include reports of anxiety, depression, irritability, and psychotic reactions. Official reports classify these psychiatric effects as uncommon or rare.

Q: What is the longest period of time someone can safely take Dinac?

A: Regulatory guidance emphasizes the principle of using the lowest effective dosage for the shortest duration possible to minimize risks. Injectable forms are generally limited to very short-term use, such as no more than two days. The appropriate treatment duration is established by a healthcare professional, with regulatory warnings noting that the risk of serious events may increase with prolonged use.

Q: Do studies show Dinac being effective in the long-term?

A: Research has been conducted that examines outcomes of using certain formulations over mid-to-long-term periods for chronic conditions like osteoarthritis and rheumatoid arthritis. These studies primarily examined and reported patient outcomes related to changes in perceived discomfort and physical functioning. However, the overall evidence quality and follow-up duration can vary across the different studies.

Q: Are there specific tests needed before starting Dinac?

A: Official documentation specifies that caution is required for patients with pre-existing kidney, liver, or heart conditions. Due to this, monitoring of certain body functions, such as blood pressure or liver enzymes, may be advised during treatment. The assessment of pre-treatment testing requirements is part of the prescribing process.

Q: Is Dinac used to treat things other than its primary listed condition?

A: Official labeling only details the specific uses (indications) for which the medicine has been formally approved by regulatory authorities. This patient information exclusively addresses only those uses detailed in the product’s official, legally approved documentation.

Q: What happens if I forget to take a dose of Dinac?

A: If a dose is missed, official patient information generally advises continuing with the next scheduled dose, thereby avoiding a double dose. Official instructions consistently state that double doses should be avoided.

Q: What should I do if I experience a severe side effect from Dinac?

A: Official patient information outlines that if signs of a severe reaction (such as difficulty breathing, sudden severe skin rash, or symptoms related to a cardiovascular event) occur, immediate cessation of the medication and seeking emergency medical services is recommended.

Q: What if I accidentally take more Dinac than prescribed?

A: If more than the recommended amount is consumed, official guidance indicates that contacting a poison control center or emergency medical services is necessary, even if no symptoms are apparent. Symptoms of overdose can include stomach pain, nausea, and vomiting.

Q: If I feel better, can I just stop taking Dinac?

A: Official information emphasizes that the course of treatment, particularly for chronic conditions, is determined by the prescriber. The regulatory documents advise that the duration of treatment, including when to stop, is a decision made by the prescribing healthcare professional based on the individual’s specific needs.

Q: Can I take Dinac if I have high blood pressure?

A: Official documents describe that Dinac can diminish the effectiveness of some medications used to treat high blood pressure. They also warn that serious cardiovascular risks may be increased in patients with existing heart conditions. The decision to use Dinac in patients with high blood pressure involves careful consideration by the prescribing professional.

Q: Is there any advice about sun exposure while using Dinac?

A: Official labeling for certain formulations of Dinac, such as topical gels, advises patients to avoid exposure of the treated area to natural or artificial sunlight. This warning is due to a documented risk of photosensitivity (increased skin sensitivity to light) with these products.

Q: Does Dinac have any known interactions with vaccines?

A: While regulatory warnings focus mainly on drug-to-drug interactions, official drug interaction resources have documented potential interactions with certain specific vaccine-related products. These documented interactions could potentially increase the risk of kidney-related issues and may require caution.

Q: How does Dinac compare to other similar medications for the same condition (without mentioning superiority)?

A: The official documentation for Dinac is intended only to provide comprehensive information about Dinac (Diclofenac) itself. The regulatory documents do not provide comparisons or assessments against other drugs used to treat the same health conditions.

Q: Why might Dinac be given for different durations of time to different people?

A: Official regulatory documents define different maximum recommended durations based on the drug’s formulation and the specific condition it is treating. For instance, injections are limited to very short-term use, while oral tablets for chronic conditions are used for longer. The duration of use is determined based on the patient's individual treatment needs and the specific indication.

Q: Do I need to take Dinac at a specific time of day?

A: The requirement for the time of day can vary by the formulation you are using. For oral tablets that are prescribed to be taken in divided doses (e.g., three times daily), official instructions advise spacing the doses out as evenly as possible to maintain a consistent amount of medicine in the body.

Q: Will Dinac interfere with my ability to drive or operate machinery?

A: Official warnings note that documented adverse effects such as dizziness or drowsiness may occur in some patients taking this medication. These effects could potentially impact a patient's ability to drive or safely operate machinery.

Q: How is the research evidence for Dinac summarized in regulatory documents?

A: Regulatory agencies summarize the evidence in sections detailing the results of clinical studies. These sections describe the types of trials performed (e.g., randomized, controlled trials) and the primary patient outcomes that were measured and reported to the authorities as proof of effect.

Q: Does Dinac require a special prescription?

A: In many regions, most oral formulations of Dinac (such as tablets and capsules) are legally available only by prescription from a licensed healthcare provider. However, some lower-strength forms, such as certain topical gels, may be available for purchase without a prescription.

Q: Can Dinac be taken on an empty stomach?

A: For some formulations, such as immediate-release tablets, it is often recommended to take them on an empty stomach (e.g., before meals) for optimal absorption. However, taking them with food may be advised to help reduce the potential for stomach irritation.

Q: Can Dinac cause long-term side effects?

A: Official documentation notes that serious adverse events, particularly related to the liver, cardiovascular, and gastrointestinal systems, can occur at any time, including during prolonged or chronic use. Chronic liver injury has been noted in very rare instances with longer durations of therapy.

How should Dinac be stored and disposed of?

How to Store and Dispose of Dinac

Dinac (diclofenac) must be stored according to official regulatory specifications to maintain its quality and efficacy.

Storage Requirements

Condition Requirement (Example for Tablets)
Temperature Store at controlled room temperature, generally not exceeding 30°C (86°F), and keep from freezing.
Protection Must be protected from moisture and stored away from direct light.
Container Dispense in a tight, light-resistant container.
Child Safety Always keep the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Dinac must be disposed of in accordance with local requirements to prevent environmental contamination, as some formulations may pose a risk to the aquatic environment. The preferred method is often a drug take-back program. If unavailable, medicines should be mixed with an unappealing substance (like dirt), sealed in a bag, and placed in the household trash; they should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dinac found in:

A-Z Index: